Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Major Adverse Cardiac Events Clear all
Terminated Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

NCT01601704
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NB32, PBO, Weight Management Program
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
45 Years and older
Enrollment
8,910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
224
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Not applicable Interventional

Echo-guided Hemodynamic Management Strategy in Elderly Patients Undergoing Noncardiac Surgery

NCT01780727
View directory record Official record
Conditions
Ventricular Dysfunction, Left, Major Adverse Cardiac Events
Interventions
EGHEM
Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
70 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jul 21, 2026, 9:42 PM EDT
Active, not recruiting No phase listed Observational

Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events

NCT06855394
View directory record Official record
Conditions
Atherosclerotic Vascular Disease, Coronary Arterial Disease (CAD), Atherosclerosis of Coronary Artery, Atherosclerosis of Arteries of the Extremities, Unspecified, Heart Diseases, Stroke, Venous Thromboembolic Disease
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
13,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 21, 2026, 9:42 PM EDT
Completed No phase listed Observational

PARA-HEART Pilot Implementation

NCT02709135
View directory record Official record
Conditions
Acute Coronary Syndrome, Chest Pain
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jul 21, 2026, 9:42 PM EDT
Completed No phase listed Observational

Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

NCT07088718
View directory record Official record
Conditions
Type 2 Diabetes, Major Adverse Cardiac Events, Cardiovascular (CV) Risk
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
44,671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 21, 2026, 9:42 PM EDT
Completed No phase listed Observational

Registry Experience at the Washington Hospital Center With Drug Eluting Stents - Synergy

NCT02823730
View directory record Official record
Conditions
Incidence of Major Adverse Cardiac Events
Interventions
PCI with Synergy Stent
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Jul 21, 2026, 9:42 PM EDT
Completed No phase listed Observational

New Technologies to Determine Carotid Plaque Vulnerability

NCT02224339
View directory record Official record
Conditions
Atherosclerosis, Carotid Artery Plaque
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

NCT03473223
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Apolipoprotein A-I [human] (apoA-I), Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
18,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
202
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jul 21, 2026, 9:42 PM EDT
Completed No phase listed Observational

Usefulness of Cardiopulmonary Exercise Testing for Cardiovascular Risk Estimation and Frailty Assessment in Liver Transplant Candidates

NCT04543825
View directory record Official record
Conditions
Cardiovascular Diseases+Liver Transplantation
Interventions
Cardiopulmonary exercise testing
Device
Lead sponsor
Andres Duarte-Rojo
Other
Eligibility
45 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Phoenix, Arizona • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Jul 21, 2026, 9:42 PM EDT
Completed No phase listed Observational

Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury

NCT04095143
View directory record Official record
Conditions
Acute Kidney Injury, Fluid Overload, Ultrasonography
Interventions
Portal vein flow, Intra-renal flow, Hepatic vein flow, Pulmonary B-lines, Dimensions of the inferior vena cava, Left ventricular function, Right ventricular function
Diagnostic Test
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Phase 4 Interventional

A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients

NCT02996721
View directory record Official record
Conditions
Death, Myocardial Infarction, Cerebral Vascular Accident, Heart Failure Hospitalization
Interventions
Vitamin D3
Biological
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

NCT01000727
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Darapladib 160 mg, Placebo, Standard Therapy
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
13,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
290
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 252 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Jul 21, 2026, 9:42 PM EDT
Terminated Phase 3 Interventional

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

NCT03510897
View directory record Official record
Conditions
Cardiac Surgery
Interventions
teprasiran, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

How Clinical and Personal Information Shape Physicians' Risk Judgments

NCT07162376
View directory record Official record
Conditions
Major Adverse Cardiac Event (MACE)
Interventions
Personal Information Disclosure
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Aspirin Resistance and Percutaneous Coronary Intervention (PCI)

NCT01103440
View directory record Official record
Conditions
Stable Angina
Interventions
Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Jul 21, 2026, 9:42 PM EDT
Recruiting No phase listed Observational

The Heart Outcomes in Pregnancy Expectations for Mom and Baby Study

NCT06517628
View directory record Official record
Conditions
Pregnancy Complications, Cardiovascular
Interventions
Purely observational study on the care and outcomes of participants with cardiovascular disease in pregnancy.
Other
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Jul 21, 2026, 9:42 PM EDT
Recruiting Phase 2Phase 3 Interventional

Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial

NCT04982419
View directory record Official record
Conditions
Acute Kidney Injury, Heart Failure, Contrast Induced Nephropathy, Coronary Angiography, Percutaneous Coronary Intervention
Interventions
Remote ischemic preconditioning, Sham remote ischemic conditioning
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Dallas, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Phase 3 Interventional

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

NCT05746559
View directory record Official record
Conditions
Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
Interventions
Placebo, Ravulizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Orange, California • San Francisco, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 21, 2026, 9:42 PM EDT
Recruiting Phase 3 Interventional

Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass

NCT06702553
View directory record Official record
Conditions
Nitric Oxide, Cardiac Surgery, Cardiopulmonary Bypass, Adult Patients Undergoing Cardiovascular Surgery With Cardiopulmonary Bypass
Interventions
Nitric Oxide Gas, Standard Care Arm
Drug
Lead sponsor
Xijing Hospital
Other
Eligibility
18 Years and older
Enrollment
3,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 21, 2026, 9:42 PM EDT
Recruiting Phase 4 Interventional

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

NCT06909565
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
112
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 21, 2026, 9:42 PM EDT
Not yet recruiting Not applicable Interventional

WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department

NCT07558265
View directory record Official record
Conditions
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Non-Invasive Positive Pressure Ventilation, High Flow Nasal Oxygen
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 21, 2026, 9:42 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383
View directory record Official record
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 79 Years
Enrollment
14,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
243
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 9:42 PM EDT
Not yet recruiting Phase 2 Interventional

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

NCT07685938
View directory record Official record
Conditions
Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor, Thoracic Cancer, Thoracic Neoplasms
Interventions
Atorvastatin and Lisinopril, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

NCT00799903
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Jul 21, 2026, 9:42 PM EDT